Whalesbook
📉 The Financial Deep Dive
Sonata Software Limited has posted a robust Q3 FY2026, with consolidated revenue reaching ₹3,080.6 Crores, marking a significant 8.4% year-on-year (YoY) growth. Normalized Profit After Tax (PAT) surged by 21.4% YoY to ₹127.5 Crores. A key highlight is the improvement in the EBITDA margin, which reached 19.5%, fulfilling the company's long-term aspiration of high teens to low 20s. Gross EBITDA saw a substantial 290 basis points (bps) improvement quarter-on-quarter (QoQ), attributed to operational enhancements, strategic right-shoring, pyramid optimization, and effective price increases. These gains were partially offset by increased costs associated with Cloud Service Providers (CSPs) and AI initiatives.
The company has declared an interim dividend of ₹1.25 per share, signaling a commitment to shareholder returns and indicating a potential move towards quarterly interim dividends.
🚀 Strategic Analysis & Impact
Sonata Software's strategic focus on modernization engineering, powered by AI and platformation, is yielding tangible results. AI now constitutes 14% of the total order book, a notable increase from the previous 10%. The company launched AgentBridge, an agentic AI platform, and strengthened its AI research ties through partnerships with IISC and Wharton. Two mid-size AI plus CSP deals were successfully closed, underscoring progress in this domain. Deep collaborations with hyperscalers like Microsoft and AWS remain central to the strategy. Large deal pursuits are a cornerstone, with 40% of the pipeline earmarked for strategic opportunities. Significant multi-year deals were secured in the BFSI sector, including one with a global financial technology and payment solutions provider and another with a leading mortgage provider, both leveraging automation and AI. Key AI wins also include modernizing legacy systems for a European digital document management firm and a US-based global software provider.
Vertical performance demonstrates a strong shift, with BFSI and Healthcare & Life Sciences now contributing 31% of total revenue, a substantial jump from 13% three years prior. North America continues to dominate, representing over 70% of total revenue. The domestic business is undergoing a strategic rebuilding phase, focusing on expanding the Microsoft channel for small and medium-sized businesses (SMC), forging partnerships with ISVs like Oracle and IBM, and integrating cloud services with other platforms. Operational efficiency saw utilization improve to 90%, with LTM attrition at 11% and 31% gender diversity.
🚩 Risks & Outlook
Despite the positive financial and strategic developments, the company faces headwinds from three of its top 10 clients. These include organizational changes and budget constraints within a large BFSI client, budget pressures in a major TMT client, and an unexpected ramp-down in a large retail client. The impact from the retail client has already been factored into the Q4 numbers. The domestic business is projected to return to YoY growth by Q2 FY2027 (on a gross contribution basis). The international business's current trajectory is expected to continue for the next one to two quarters. Management guidance indicates that the EBITDA margin is projected to remain stable within the 18-21% range.
Impact Rating: 7/10 - The strong AI integration and vertical growth are positive, but client-specific headwinds pose a near-term risk that investors must monitor closely. The outlook for domestic business recovery is also a key watch point.